Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling
Ido Yofe, Tomer Landsberger, Adam Yalin, Isabelle Solomon, Cristóbal Costoya, Dafne Franz Demane, Mansi Shah, Eyal David, Chamutal Borenstein, Oren Barboy, Ignacio Matos, Karl S. Peggs, Sergio A. Quezada, Ido Amit
Topics & Concepts
ImmunotherapyCytotoxic T cellImmune systemTumor microenvironmentCancer researchImmunologyInnate immune systemT cellInterferonBiologyCTLA-4Immune checkpointBlocking antibodyMyeloidAntibodyBlockadeReceptorIn vitroBiochemistryImmune Cell Function and InteractionCancer Immunotherapy and BiomarkersT-cell and B-cell Immunology